Login
Navigate Fool.com
Will ETRM beat
the market?

EnteroMedics (NASDAQ: ETRM)

Community Rating: 3 Stars: Appealing

1.51 -0.03 (-1.94%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.53
Previous Close $1.54
Daily Range $1.51 - $1.53
52-Week Range $1.00 - $2.66
Market Cap $101.5M
P/E Ratio -3.58
Dividend (Yield) $0.00 (0.0%)
Volume 29,314
Average Daily Volume 2,023,572
Current FY EPS -$0.41

How do you think ETRM
will perform against the market?

Top ETRM Bull/Bear Pitches

 

aquiline1 (< 20)
Submitted September 16, 2009

Wish I could have rated it when I bought it.

1 Replies Reply Report this Post
 

hanginout (< 20)
Submitted June 17, 2009

Trying for a weigh loss treatment. This is the only possibility and ETRM doesn't have the funding to pull off the clinical trials needed to get it far enough along to even find out if it works. A on … More

2 Replies Reply Report this Post

News & Commentary Rss Feed

An Obesity Treatment Doomed for Failure?

There's nothing blocking this sell-off.

Five Analyst Stock Picks With 100% or More Implied Upside

Analysts Target 150% Upside in EnteroMedics Stock Price

Sector Update: Healthcare Mixed Pre-Market; EnteroMedics Up 3% on Maestro Rechargeable System Progre

Sector Update: Healthcare Mixed Pre-Market; EnteroMedics Up 3% on Maestro Rechargeable System Progress

Sector Update: Healthcare

Biotech and BioHeath Stocks Raising Capital, Secondary Offerings

Today’s Market Winners and Losers

U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH

U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH

UPDATE: EnteroMedics Shares Plunge as Obesity Device Fails Trial

See More ETRM News...

Sector

Healthcare

Industry

Healthcare Information Services

EnteroMedics (ETRM) Description

A development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity its associated co-morbidities and other gastrointestinal disorders. Website: http://www.enteromedics.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks